Samsung Biologics announced that it will start partial operation within this year in connection with its fourth plant currently under construction. It also introduced that it has already won orders for consignment production from three global pharmaceutical companies. John Lim, CEO of Samsung BioLogics, made the remarks at a press conference at the JPMorgan Healthcare Conference held online on the 13th.

He explained that the completion schedule of the four plants currently under construction has been moved up by about six months. Samsung Biologics announced its plan to establish a 256,000-liter plant in 2020. The fourth plant, which is under construction with a total floor area of 240,000 square meters